Barclays lowered the firm’s price target on Avantor (AVTR) to $18 from $23 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Avantor price target lowered to $24 from $29 at RBC Capital
- Avantor price target lowered to $24 from $27 at TD Cowen
- Avantor announces completed expansion at European manufacturing site
- Avantor price target lowered to $18 from $22 at Citi
- Trump Trade: President to impose 25% tariffs on steel, aluminum imports
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue